Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.73 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27662594 | 1.00 | FFAR1 (0.73) | FFAR1S1PR5S1PR1PTGDR2ALOX5 | |
| SCHEMBL27662443 | 1.00 | FFAR1 (0.73) | FFAR1S1PR5S1PR1PTGDR2ALOX5 | |
| SCHEMBL25033296 | 0.83 | SRD5A2 (0.57) | FFAR1SRD5A2AKR1B1CNR2POLB | |
| SCHEMBL11661233 | 0.82 | FFAR1 (0.66) | FFAR1S1PR5S1PR1PTGDR2ALOX5 | |
| SCHEMBL961317 | 0.81 | POLB (0.73) | FFAR1SRD5A2AKR1B1CNR2POLB | |
| SCHEMBL10565666 | 0.81 | FFAR1 (0.50) | FFAR1S1PR5S1PR1PTGDR2SRD5A2 | |
| SCHEMBL11490486 | 0.81 | SRD5A2 (0.50) | FFAR1SRD5A2AKR1B1CNR2POLB | |
| SCHEMBL6744396 | 0.81 | FFAR1 (0.56) | FFAR1S1PR5S1PR1ALOX5LTB4R | |
| SCHEMBL6904351 | 0.80 | FFAR1 (0.61) | FFAR1S1PR5S1PR1ALOX5LTB4R | |
| SCHEMBL7713616 | 0.80 | POLB (0.56) | FFAR1SRD5A2AKR1B1CNR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | FFAR1 153/4885S1PR5 721/4885S1PR1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.